Company: IMRX
Filing Date: 2025-09-03
Form Type: S-3
Source: 0001104659-25-086561
Chunk: 16

Company: Immuneering Corp
Filing Date: 2025-09-03
Form: S-3
Chunk 16
---
 | the number of shares of our Class A common stock that would be issuable upon exercise of the Pre-Funded Warrant in accordance with the terms of the Pre-Funded Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. |

As used above, the “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if our Class A common stock is then listed or quoted for trading on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing), any such market being referred to as the Trading Market, the daily volume-weighted average price of the Class A common stock for such date (or the nearest preceding date) on the Trading Market on which the Class A common stock are then listed or quoted as reported by Bloomberg Financial L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)); (b) if our Class A common stock are then quoted for trading on the OTCQB or OTCQX operated by OTC Markets Group, the volume weighted average price of the our commons stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if our Class A common stock is then quoted for trading on the Pink Open Market operated by OTC Markets Group (or a similar organization or agency succeeding to its functions of reporting prices), the average of the bid prices of any market makers for such security as reported on the Pink Open Market as of such time of determination, or (d) in all other cases, the fair market value of one share of Class A common stock as determined by an independent appraiser selected in good faith by us and reasonably acceptable to the holders of a majority in interest of the Pre-Funded Warrants then outstanding, the fees and expenses of which shall be paid by us. The Purchase Warrants also include certain rights upon the occurrence of a “fundamental transaction” (as described in the Purchase Warrants) that is either (1) an all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a fundamental transaction in which the successor or acquiring corporation has no